Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was founded in 1942 and is headquartered in Philadelphia, Pennsylvania.
IPO Year:
Exchange: NYSE
Website: lannett.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/31/2021 | $7.00 → $6.00 | Neutral | Roth Capital |
4 - LANNETT CO INC (0000057725) (Issuer)
4 - LANNETT CO INC (0000057725) (Issuer)
4 - LANNETT CO INC (0000057725) (Issuer)
4 - LANNETT CO INC (0000057725) (Issuer)
4 - LANNETT CO INC (0000057725) (Issuer)
4 - LANNETT CO INC (0000057725) (Issuer)
4 - LANNETT CO INC (0000057725) (Issuer)
4 - LANNETT CO INC (0000057725) (Issuer)
4 - LANNETT CO INC (0000057725) (Issuer)
4 - LANNETT CO INC (0000057725) (Issuer)
EFFECT - LANNETT CO INC (0000057725) (Filer)
EFFECT - LANNETT CO INC (0000057725) (Filer)
EFFECT - LANNETT CO INC (0000057725) (Filer)
EFFECT - LANNETT CO INC (0000057725) (Filer)
EFFECT - LANNETT CO INC (0000057725) (Filer)
EFFECT - LANNETT CO INC (0000057725) (Filer)
EFFECT - LANNETT CO INC (0000057725) (Filer)
EFFECT - LANNETT CO INC (0000057725) (Filer)
15-12G - LANNETT CO INC (0000057725) (Filer)
S-8 POS - LANNETT CO INC (0000057725) (Filer)
SC 13G/A - LANNETT CO INC (0000057725) (Subject)
SC 13G/A - LANNETT CO INC (0000057725) (Subject)
SC 13G/A - LANNETT CO INC (0000057725) (Subject)
SC 13G/A - LANNETT CO INC (0000057725) (Subject)
SC 13G/A - LANNETT CO INC (0000057725) (Subject)
SC 13G/A - LANNETT CO INC (0000057725) (Subject)
SC 13G/A - LANNETT CO INC (0000057725) (Subject)
SC 13G/A - LANNETT CO INC (0000057725) (Subject)
SC 13G/A - LANNETT CO INC (0000057725) (Subject)
Submission status for LANNETT CO INC's drug LEVOFLOXACIN (SUPPL-11) with active ingredient LEVOFLOXACIN has changed to 'Approval' on 09/20/2024. Application Category: ANDA, Application Number: 205222, Application Classification: Labeling
Submission status for LANNETT CO INC's drug MYCOPHENOLATE MOFETIL (SUPPL-7) with active ingredient MYCOPHENOLATE MOFETIL has changed to 'Approval' on 08/13/2024. Application Category: ANDA, Application Number: 214525, Application Classification: REMS
Submission status for LANNETT CO INC's drug SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (ORIG-1) with active ingredient MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE has changed to 'Approval' on 07/15/2024. Application Category: ANDA, Application Number: 209941, Application Classification:
Submission status for LANNETT CO INC's drug PREDNISOLONE (SUPPL-13) with active ingredient PREDNISOLONE has changed to 'Approval' on 06/05/2024. Application Category: ANDA, Application Number: 040775, Application Classification: Labeling
Submission status for LANNETT CO INC's drug BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (SUPPL-17) with active ingredient BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE has changed to 'Approval' on 03/20/2024. Application Category: ANDA, Application Number: 205022, Application Classification: REMS
Submission status for LANNETT CO INC's drug OXYCODONE AND ACETAMINOPHEN (SUPPL-12) with active ingredient ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE has changed to 'Approval' on 03/13/2024. Application Category: ANDA, Application Number: 207333, Application Classification: Labeling
Submission status for LANNETT CO INC's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (SUPPL-4) with active ingredient AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 02/27/2024. Application Category: ANDA, Application Number: 214403, Application Classification: Labeling
Submission status for LANNETT CO INC's drug LISDEXAMFETAMINE DIMESYLATE (SUPPL-1) with active ingredient LISDEXAMFETAMINE DIMESYLATE has changed to 'Approval' on 02/14/2024. Application Category: ANDA, Application Number: 215802, Application Classification: Labeling
Submission status for LANNETT CO INC's drug TRIAMTERENE AND HYDROCHLOROTHIAZIDE (SUPPL-12) with active ingredient HYDROCHLOROTHIAZIDE; TRIAMTERENE has changed to 'Approval' on 01/08/2024. Application Category: ANDA, Application Number: 201407, Application Classification: Labeling
Submission status for LANNETT CO INC's drug PRAZOSIN HYDROCHLORIDE (ORIG-1) with active ingredient PRAZOSIN HYDROCHLORIDE has changed to 'Approval' on 01/03/2024. Application Category: ANDA, Application Number: 214083, Application Classification:
Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $6.00 from $7.00 previously
Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $7.00 from $7.50 previously
Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo
Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive Conversations with Key Secured Creditors Toward a Balance Sheet Strengthening, Recapitalization or Restructuring Transaction Ongoing As Company Enters Grace Period for Failure to Pay Interest on Convertible Notes TREVOSE, Pa., April 4, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) (the "Company") today shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.
Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin
TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m. Eastern Time on February 6, 2023. Beginning February 7, 2023, the company's common stock will trade on a split-adjusted basis. The common stock will continue to trade on the New York Stock Exchange (NYSE) under the symbol "LCI," but will trade under the new CUSIP number 516012 200. The reverse stock split was approved by Lannett Company's stockholders at the company's Annual Meeting of Stockholders held on January 25, 2023.
TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners a
--Announces Positive Animal PK Study Results of Insulin Aspart Versus US NovoLog®-- --Analysis of Pivotal Trial Results of Insulin Glargine Nearly Completed, BLA Filing Timeline Slightly Delayed, But Potential Launch Timing Remains in Range-- TREVOSE, Pa., Jan. 4, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products. Lannett is developing both products with its strategic alliance partner, the HEC Group of companies (HEC). The company s
TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin aspart development programs, that will provide a patent sublicense to the company and its strategic alliance partner within the HEC Group of companies (HEC). Under the agreement, Lannett and HEC will, in exchange for its financial contribution, receive a sub-license to a licensing arrangement
Q1 Business and Financial Highlights: Net Sales were $75.1 MillionGross Margin 17%, Adjusted Gross Margin 18%Net Sales, Gross Margin and Adjusted Gross Margin Increased from Preceding QuarterCash Was $78 Million at September 30Sold Several Discontinued ANDAs for Approximately $3 MillionPipeline Updates: Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023;Generic FLOVENT® DISKUS® ANDA Filing Anticipated Spring of Next Year, Earlier Granted CGT Status by FDA TREVOSE, Pa., Nov. 2, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its f
TREVOSE, Pa., Oct. 26, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 855-327-6837 from the U.S. or Canada, or 631-891-4304 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners ar
--Approval Allows Site to Rapidly Expand Liquid Drug Manufacturing-- PHILADELPHIA, Oct. 21, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it has received approval from the US Food and Drug Administration (FDA) to manufacture Numbrino®, the company's branded topical anesthetic product, at its main plant in Seymour, Indiana. The company previously manufactured Numbrino and other liquid drug products at its Carmel, New York plant, which it sold in March of this year as part of a restructuring and cost reduction plan. "We completed the liquid drug buil
Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo
Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin
TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners a
Q1 Business and Financial Highlights: Net Sales were $75.1 MillionGross Margin 17%, Adjusted Gross Margin 18%Net Sales, Gross Margin and Adjusted Gross Margin Increased from Preceding QuarterCash Was $78 Million at September 30Sold Several Discontinued ANDAs for Approximately $3 MillionPipeline Updates: Completed Dosing of Subjects in the Pivotal Biosimilar Insulin Glargine Clinical Trial, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023;Generic FLOVENT® DISKUS® ANDA Filing Anticipated Spring of Next Year, Earlier Granted CGT Status by FDA TREVOSE, Pa., Nov. 2, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its f
TREVOSE, Pa., Oct. 26, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 855-327-6837 from the U.S. or Canada, or 631-891-4304 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners ar
Q4 Business and Financial Highlights: Net Sales were $74.2 MillionAdjusted Gross Margin Better than Expected, Improved vs Q3 Cash Was $88 Million at June 30Completed Major Elements of November 2021 Restructuring PlanPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Over 90% Complete, Top-line Results Anticipated by Year End; BLA Filing On Track for First Half of 2023Expect to File IND for Biosimilar Insulin Aspart by First Half of 2023Generic FLOVENT® DISKUS® Product On Track for ANDA Filing Early Next Calendar Year, Granted CGT Status by FDA Expect Partner to Commence Pilot PK Trials for Generic Spiriva® Handihaler® by Year End 2022Licensed a Filed ANDA for Mesalamine Del
TREVOSE, Pa., Aug. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2022 fourth quarter and full year on Wednesday, August 24, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com
Q3 Business and Financial Highlights: Net Sales were $78.4 Million Cash in Excess of $106 Million at March 31Completed Sale of Liquid Manufacturing Plant for $10.5 Million; Major Elements of November 2021 Restructuring Plan Expected to be Completed by June 30Pivotal Biosimilar Insulin Glargine Clinical Trial ProgressingTREVOSE, Pa., May 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its fiscal 2022 third quarter ended March 31, 2022. "For the quarter, ongoing competitive pressures and unusually high product returns for a few key
TREVOSE, Pa., April 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance and answer questions. The conference call will be available to interested parties by dialing 877-344-8082 from the U.S. or Canada, or 213-992-4618 from international locations. The call will be broadcast via the Internet at www.Lannett.
TREVOSE, Pa., Feb. 3, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today reported financial results for its fiscal 2022 second quarter ended December 31, 2021. "For the quarter, ongoing and increasing competitive pricing pressure across our product offering negatively impacted net sales and gross margin," said Tim Crew, chief executive officer of Lannett. "While we anticipate this pricing environment to persist over the near term, we continue to execute on our core strategies to build our product pipeline, advance our durable insulin and respiratory assets and reduce